about
CpG Oligodeoxynucleotides Enhance the Activities of CD8+ Cytotoxic T-Lymphocytes Generated by Combined hMUC1 Vaccination and hNIS Radioiodine Gene Therapy.Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine.Dengue vaccines: state of the art.Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis.Construction of a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaACharacterization of the ribonuclease activity on the skin surface.Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccinationAbeta DNA vaccination for Alzheimer's disease: focus on disease prevention.T cell-mediated immunotherapy of metastases: state of the art in 2005.Strategies for DNA vaccine delivery.Bacterial magnetic particles as a novel and efficient gene vaccine delivery system.Progress in the development of genetic immunization.Comparative study of synonymous codon usage variations between the nucleocapsid and spike genes of coronavirus, and C-type lectin domain genes of human and mouse.RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection.A combined approach of hollow microneedles and nanocarriers for skin immunization with plasmid DNA encoding ovalbumin.Magnetic Nanovectors for the Development of DNA Blood-Stage Malaria Vaccines.Electroporation for DNA immunization: clinical application.DNA vaccines for targeting bacterial infections.Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis.Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus.Membrane and envelope virus proteins co-expressed as lysosome associated membrane protein (LAMP) fused antigens: a potential tool to develop DNA vaccines against flaviviruses.DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN.Quantitative evaluation of DNA dissociation from liposome carriers and DNA escape from endosomes during lipid-mediated gene delivery.Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus.
P2860
Q33704106-AD482D0A-1DB8-445D-8971-DC5BDB6411F6Q33787778-5C528B08-CA2F-4581-A614-5BDA35B2B0B7Q34038849-EA16BF89-BFF5-4D1A-ADF9-59B255716EB0Q34109652-F9ABDEB9-6009-4AD5-9B47-EAB68A2ACABAQ34111604-230B41F9-7E19-44BE-B9CC-C20ADA8AD719Q34382425-7C90906C-5E4D-4DB8-85B2-EE740C8C38AAQ34880734-78ACD9B3-7271-4E2B-ACBB-EDBE7DF04463Q34994496-3AC804D2-1D3C-4957-AA2E-3CB535E9EEB9Q35156471-216FAA77-8AA5-40CB-9D4F-172258A9EB96Q36210864-4D6104E6-0888-4B2D-821B-8DC4170E4456Q36316818-69A1447B-B5D0-46A3-BB22-9F83F48D1F1CQ36460540-9222563C-7793-4679-8C1E-AFFCFB1F9C4DQ37316018-EF8807D9-F29A-400D-B28E-54108C83B187Q37411209-553B6CF3-D497-4C7A-A7DD-87E140044A94Q37582824-ACE65B46-050E-4415-B946-2360BE8D9782Q37623985-1E4F8064-9554-4116-84A4-EF30C10995FCQ37676195-619ADE95-00AF-49DA-BFD5-EA494C2D225EQ37744992-EBC8E4E5-568A-4D56-A1BE-640904AF5929Q37771943-53C04835-8F00-406A-A774-9AD12D43E55EQ40223076-01D01EC5-B9B2-4F90-B54B-F7EFD63C3DB0Q40274279-2BA8977C-A037-4468-8C3D-0665D2A15F1EQ40374618-547C1561-C149-4E9C-9EF8-52B6222B663AQ40540571-D5D3A5F0-CA29-46EF-A962-E400FA5A10F3Q42548978-B0AFC203-2405-4208-94A6-F4338E7C8620Q42990749-BC361EA9-28B9-4B60-9996-6127E5AFAC8A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Technical and regulatory hurdles for DNA vaccines.
@ast
Technical and regulatory hurdles for DNA vaccines.
@en
type
label
Technical and regulatory hurdles for DNA vaccines.
@ast
Technical and regulatory hurdles for DNA vaccines.
@en
prefLabel
Technical and regulatory hurdles for DNA vaccines.
@ast
Technical and regulatory hurdles for DNA vaccines.
@en
P2093
P1476
Technical and regulatory hurdles for DNA vaccines.
@en
P2093
Jeffrey B Ulmer
John Donnelly
Karin Berry
P304
P356
10.1016/S0020-7519(03)00056-0
P577
2003-05-01T00:00:00Z